Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

NCT00498914 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

41

Enrollment

INDUSTRY

Sponsor class

Stopped Futility boundary at interim analysis not met

Conditions

Lymphoma, Large-Cell, Diffuse
Lymphoma, B-Cell Refractory

Interventions

DRUG: YM155

Sponsor

Astellas Pharma Inc